Investor Updates

22. December 2005
U.S. Food and Drug Administration extends prophylaxis indication for Tamiflu to patients between 1 to 12 years of age
more

16. December 2005
Roche announces successful completion of four pivotal Phase III clinical trials for CERA
more

15. December 2005
Tamiflu gains positive opinion in Europe and Switzerland for prevention of influenza in children 1 to 12 years
more

14. December 2005
Changes on Corporate Executive Committee and Board of Directors of Roche
more

13. December 2005
Roche and SystemsX collaborate in diabetes research
more

12. December 2005
MabThera maintenance therapy dramatically improves survival for patients with lymphoma
more

12. December 2005
Invitation to conference call on phase III results for MabThera in NHL maintenance, Tuesday 13th December, 2005
more

12. December 2005
Roche update on Tamiflu global supply to meet future world demands - from partnerships to regional sub-licenses
more

30. November 2005
Roche and BioCryst collaborate on clinical compound BCX-4208 for transplantation and autoimmune diseases
more

19. November 2005
FDA advisory committee affirms safety of Tamiflu in children
more

17. November 2005
Actemra monotherapy significantly slows down damage to joints in patients with early aggressive rheumatoid arthritis
more

16. November 2005
Bonviva intravenous injection for postmenopausal osteoporosis confirmed effective over 2 years
more

16. November 2005
MabThera - a unique approach providing lasting benefits for patients with rheumatoid arthritis
more

16. November 2005
Roche and Gilead end dispute on influenza drug Tamiflu
more

11. November 2005
Early results show Pegasys working where Peg-Intron has failed
more

10. November 2005
Reminder: Invitation to Roche Analyst Briefing at American College of Rheumatology Meeting, November 16th
more

09. November 2005
Media Briefing - Pandemic influenza and Tamiflu production
more

07. November 2005
Roche announces further progress in Tamiflu production expansion
more

03. November 2005
Tarceva receives approval for pancreatic cancer in the United States
more

02. November 2005
Interim analysis of phase III trial shows Xeloda plus gemcitabine improved overall survival in patients with first-line pancreatic cancer
more

01. November 2005
Roche and Protein Design Labs to jointly develop daclizumab in transplant maintenance therapy
more

20. October 2005
Invitation to Roche Analyst Briefing at American College of Rheumatology Meeting
more

19. October 2005
Roche continues to post strong growth through third quarter
more

18. October 2005
Reminder - Roche´s Third Quarter Sales 2005 Release
more

18. October 2005
Actemra Japanese phase III rheumatoid arthritis data to be presented at the American College of Rheumatology meeting in November
more

11. October 2005
Roche Diagnostics to co-develop IT-enabled prototype psychiatric pharmacogenomics tool
more

07. October 2005
Roche becomes founding member of ICRC Corporate Support Group
more

07. October 2005
Roche launches novel system for High-throughput DNA Sequencing
more

27. September 2005
Roche´s Third Quarter Sales 2005 Release
more

21. September 2005
Tarceva approved in Europe for lung cancer
more

19. September 2005
Roche reselected for inclusion in Dow Jones Sustainability and FTSE4Good Index series
more

19. September 2005
Once-monthly oral Bonviva approved for postmenopausal osteoporosis in Europe
more

14. September 2005
Fourth phase III study shows Herceptin plus chemotherapy improved disease-free survival in early-stage HER2-positive breast cancer
more

13. September 2005
Tamiflu Shown to Reduce Risk of Death in Patients with Influenza
more

13. September 2005
Pegasys plus Ribavirin awarded priority review status by Japanese Regulatory Agency
more

12. September 2005
Roche announces settlement agreement with Promega
more

08. September 2005
Once-monthly oral Bonviva approved for postmenopausal osteoporosis in Switzerland
more

06. September 2005
Roche files first rheumatoid arthritis indication for MabThera in Europe
more

31. August 2005
Biogen Idec and Genentech submit a supplemental Biologics License Application for FDA review of Rituxan for the treatment of rheumatoid arthritis
more

04. August 2005
Full reconciliation of Chugai results into IFRS
more

02. August 2005
Launch of key cardiac marker NT-proBNP on the cardiac reader, Roche´s Point of Care analyzer
more

20. July 2005
Roche posts very strong interim results
more

19. July 2005
Reminder: 20 July - Roche´s 2005 Half Year Results and Report
more

19. July 2005
Roche files new indication for Tamiflu in Europe for prevention of influenza in children 1 to 12 years
more

19. July 2005
Roche acquires Swiss based GlycArt Biotechnology to strengthen expertise in therapeutic antibody research
more

14. July 2005
New cancer drug Tarceva demonstrates significant improvement in survival, symptoms and quality of life in lung cancer says landmark New England Journal of Medicine study
more

30. June 2005
Second New England Journal of Medicine paper establishes Pegasys as a first-line therapy in chronic hepatitis B
more

29. June 2005
US Court of Appeals decides in favour of Roche on Empagran case
more

28. June 2005
Xenical gains European approval for use in young people
more

27. June 2005
Bonviva, the first once-monthly oral tablet for osteoporosis, receives positive opinion in Europe
more

27. June 2005
Tarceva receives positive opinion in EU for the treatment of patients with lung cancer
more

24. June 2005
20 July - Roche´s 2005 Half Year Results and Report
more

21. June 2005
Media Briefing - Pharmacogenomics - the future is now
Roche paving the way for personalised medicine more

17. June 2005
Pegasys Plus Ribavirin Significantly More Effective than Monotherapy in Landmark Japanese Clinical Trial
more

17. June 2005
Biologics Manufacturing Facility to be Purchased by Genentech from Biogen Idec
more

15. June 2005
FDA approves oral Xeloda for the adjuvant (after surgery) treatment of colon cancer
Colon cancer patients have access to a new effective and more convenient treatment more

09. June 2005
Preliminary phase IIb study showed MabThera improved symptoms in rheumatoid arthritis patients who failed one or more disease-modifying anti-rheumatic drugs
Improvement shown to be independent of administration of corticosteroids more

09. June 2005
New data confirm once-monthly oral treatment for osteoporosis is highly effective over two years
MOBILE 2-year results announced today reinforce efficacy, safety and tolerability of Bonviva more

07. June 2005
Roche dedicates world´s largest PCR-manufacturing facility in New Jersey
New site for 800 people; investment of more than 150 million US dollars more

06. June 2005
New CERA year-long data show sustained and stable control of anemia in dialysis patients
Results achieved with once-monthly dosing more

03. June 2005
NeoRecormon offers patients maximum anaemia control with minimum injection discomfort compared to Aranesp
more

27. May 2005
European approval for Roche´s new Invirase 500 mg tablet for the treatment of HIV
New Invirase 500 mg tablet significantly reduces pill burden for patients more

17. May 2005
Twice as many long-term survivors with HER2-positive metastatic breast cancer following treatment with Herceptin
Two-year follow-up results show powerful new evidence for Herceptin as the foundation of care in HER2-positive metastatic ... more

17. May 2005
New US approval makes Pegasys the first and only pegylated interferon indicated for the treatment of chronic hepatitis B
Pegasys, the most prescribed hepatitis C medication in the US, is now approved for 1.25 million Americans with chronic hepatitis ... more

16. May 2005
Herceptin plus chemotherapy improved disease-free survival and overall survival in adjuvant setting for early-stage Her2-positive breast cancer patients
Results from two phase III adjuvant trials showed that adding Herceptin to chemotherapy reduced the risk of breast cancer ... more

16. May 2005
MabThera maintenance therapy doubles time of remission for lymphoma patients when used after MabThera and chemotherapy
more

16. May 2005
Avastin plus chemotherapy showed doubling of time without cancer progression in phase III trial of first-line metastatic breast cancer patients
Study also showed improvement in overall survival at interim analysis more

16. May 2005
Phase III trial of Avastin plus chemotherapy showed 30 percent improvement in overall survival in first-line non-squamous, non-small cell lung cancer
First phase III study to extend median survival beyond one year in advanced lung cancer more

16. May 2005
Phase III study of Tarceva in combination with chemotherapy improves survival in pancreatic cancer patients
Data presented at plenary session at annual ASCO meeting more

16. May 2005
Herceptin delivers impressive improvement in disease-free survival for women with early-stage HER2-positive breast cancer
Results from HERA showed that Herceptin adjuvant therapy following chemotherapy reduced the risk of breast cancer recurrence ... more

11. May 2005
Reminder- Invitation to Roche event on US Diagnostics business
more

10. May 2005
Roche Diagnostics Signs Research Agreement with Lilly to Confirm Gene-Based Targets
Goal is to Begin a Personalized Medicine Collaboration to Identify Patients Most Likely to Respond to Two Leading Cancer Medications more

10. May 2005
Reminder: Invitation to the Roche ASCO Analyst Briefing on May 16th
more

02. May 2005
Tarceva - supplemental new drug application filed in the US for treatment of pancreatic cancer
more

02. May 2005
FDA clears Roche´s new Accu-Chek Aviva blood glucose meter
Accu-Chek Aviva combines dependability and ease of use to help in the management of diabetes more

28. April 2005
Herceptin - international study confirms significant improvement in disease-free survival for women with early-stage HER2-positive breast cancer
Interim analysis of HERA study based on almost 5,100 patients confirms Herceptin's potential to reduce risk of cancer ... more

26. April 2005
Herceptin improves survival for the first time in women with early-stage HER2-positive breast cancer
Joint interim analysis of two large phase III clinical trials provides first positive data of a targeted therapy after initial ... more

25. April 2005
FDA approves Roche's Cobas AmpliScreen Hepatitis B Test for use in screening Blood Donors
Test is first nucleic acid Hepatitis B blood screening test approved by FDA more

22. April 2005
Invitation to the Roche ASCO Analyst Briefing on May 16th
more

19. April 2005
Roche files supplemental new drug application to extend prophylaxis indication for Tamiflu to patients between one to 12 years of age
Leading prescription antiviral medication plays key role in influenza prevention and treatment more

19. April 2005
Roche leads off in 2005 with impressive first quarter - pharmaceutical sales grow three times as fast as the global market
more

18. April 2005
Reminder - Roche's First Quarter Sales 2005 Release
more

18. April 2005
Roche clinical trial registry and results database launched on www.roche-trials.com
High degree of transparency to enhance communication between Roche, patients and doctors more

15. April 2005
Interim analysis shows improved progression-free survival with Avastin for patients with previously untreated metastatic breast cancer
Third cancer to show benefit with Avastin more

13. April 2005
Invitation to Roche event on US Diagnostics business
Presentations and tour of US Indianapolis facility more

12. April 2005
Roche and GlaxoSmithKline announce promotion agreement for Xenical in the US
more

06. April 2005
MabThera significantly improves symptoms in patients with rheumatoid arthritis who inadequately responded to anti-TNFα therapies
Third large randomised trial to evaluate efficacy and safety of MabThera in RA more

05. April 2005
Chugai: A Revision of Financial Outlook for Fiscal Year 2005 (January 1 ~ December, 2005)
more

01. April 2005
Xeloda wins EU approval for adjuvant therapy in the treatment of colon cancer
Colon cancer patients have access to a new, more convenient and safer treatment option compared to the current standard of ... more

29. March 2005
Roche´s First Quarter Sales 2005 Release
more

29. March 2005
FDA approves once-monthly Boniva for osteoporosis
First ever monthly single tablet for any disease more

22. March 2005
New lung cancer medicine Tarceva receives first European approval
Swiss authority clears first and only medicine in its class that prolongs survival in advanced lung cancer more

15. March 2005
Revolutionary cancer treatment Avastin now proven to extend life also for lung cancer patients
Interim analysis shows first ever positive results in untreated patients with a biological therapy for non-small cell lung ... more

08. March 2005
Roche presents effects of IFRS changes on the Group results
more

04. March 2005
Reminder - Invitation to Roche IFRS Workshop in London
more

02. March 2005
New data presented at major AIDS meeting show Fuzeon plus an active protease inhibitor provides maximal HIV suppression in treatment experienced patients
Large trials of investigational drugs support powerful treatment strategy for triple-class experienced patients more

28. February 2005
Roche increases dividend by 21 percent
Annual General Meeting approves eighteenth consecutive annual dividend increase - Board members Humer, Hoffmann and Bell re-elected ... more

28. February 2005
US approves Pegasys and Copegus as first hepatitis C treatment for HIV patients
Pegasys combination therapy offers new hope against a leading cause of death in patients with HIV more

25. February 2005
Pegasys approved in the European Union for the treatment of chronic hepatitis B
Only pegylated interferon approved for the treatment of chronic hepatitis B more

21. February 2005
Roche´s New Invirase 500 mg HIV Treatment Receives Positive Opinion from European Authorities
New tablet will offer significantly reduced pill burden more

18. February 2005
Xeloda: positive opinion in EU for treatment of colon cancer after surgery
New indication will allow more patients to benefit from effective and convenient oral cancer treatment more

10. February 2005
Full reconciliation of Chugai results into IFRS
more

03. February 2005
Invitation to Roche IFRS Workshop in London
more

03. February 2005
Pegasys combination therapy approved for the treatment of hepatitis C and HIV co-infection in Europe
Pegasys becomes the first and only hepatitis C treatment indicated for patients suffering from both HIV and HCV more

02. February 2005
Roche in 2004: Net income doubled - further significant improvement in operating profitability and financial position
more

01. February 2005
Reminder - Roche´s Full Year Results and Report for 2004
more

28. January 2005
Avastin extends survival in patients with advanced colorectal cancer; new data supports its combination with widely prescribed chemotherapy
Study adds to the body of evidence showing the benefits of Avastin with different colorectal cancer treatment regimens more

28. January 2005
Breakthrough drug Tarceva provides new hope for patients with advanced pancreatic cancer
New data shows significant improvement in overall survival when Tarceva is added to chemotherapy more

21. January 2005
Roche to launch publicly accessible databases for clinical trials
Enhanced transparency through electronic databases for clinical trial protocol registration and reporting of results more

21. January 2005
Pegasys receives positive opinion in the European Union for the treatment of chronic hepatitis B
First pegylated interferon to be indicated for treating chronic hepatitis B more

14. January 2005
Innovative Roche cancer medicine Avastin approved in EU
First treatment of its kind with proven survival benefit for patients with advanced colorectal cancer more

12. January 2005
Roche´s AmpliChip CYP450 Test receives FDA clearance
First microarray-based diagnostic test for detection of genetic variations that can influence drug efficacy and adverse drug ... more

05. January 2005
Roche's Full Year Results and Report for 2004
more

03. January 2005
Sale of Roche Consumer Health to Bayer completed
more